Evidence map›Paper›PMID 34715880›Full record

ArticleWorld journal of surgical oncology2021

The prognostic value of arginase-1 and glypican-3 expression levels in patients after surgical intrahepatic cholangiocarcinoma resection.

Zeyuan Qiang, Haofeng Zhang, Shuai Jin, Cao Yan, Zhen Li, Lianyuan Tao, Haibo Yu

Open access · goldAbstract read
In one paragraph

Article in World journal of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zeyuan QiangDepartment of Hepatobiliary Surgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Haofeng ZhangDepartment of Hepatobiliary Surgery, Medical College of Zhengzhou University, Zhengzhou, China.
Shuai JinDepartment of Hepatobiliary Surgery, Medical College of Zhengzhou University, Zhengzhou, China.
Cao YanDepartment of Hepatobiliary Surgery, Medical College of Zhengzhou University, Zhengzhou, China.
Zhen LiDepartment of Pathology, Henan Provincial People's Hospital, Zhengzhou, China.
Lianyuan TaoDepartment of Hepatobiliary Surgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Haibo YuDepartment of Hepatobiliary Surgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China. yhb2101661@163.com.
Zhengzhou University · CNHenan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to investigate the prognostic value of arginase-1 (Arg-1) and glypican-3 (GPC-3) in patients with intrahepatic cholangiocarcinoma (ICC).

methodsTwo hundred and thirty-seven patients with ICC were included in this study. All patients had undergone radical surgery and had complete clinical information. Immunohistochemistry was used to assess the levels of Arg-1 and GPC-3 in ICC tissues. Univariate and multivariate analyses were conducted to identify independent risk factors in ICC. The relationship between Arg-1 and GPC-3 levels and patient survival was determined using the Kaplan-Meier method.

resultsHigh Arg-1 and GPC-3 expression levels were associated with poor prognosis in patients with ICC, and they could be as new prognostic biomarkers in ICC.

conclusionArg-1 and GPC-3 can serve as independent prognostic biomarkers in ICC.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaArginaseGlypicansHumansPrognosisARG1 protein, humanArginaseGlypicansGPC3 protein, humanArginase-1Glypican-3ImmunohistochemistryIntrahepatic cholangiocarcinomaPrognosis

Identifiers

PMID34715880
PMCPMC8556943
OpenAlexW3211196335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.